{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-004224","form_type":"8-K","ticker":"RVPH","cik":"0001742927","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2025-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.685399+00:00","generated_at":"2026-05-26T17:01:03.705455+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Reviva Pharmaceuticals adjusts exec compensation; CEO salary $565k, options at $1.80","bullets":["Dr. Bhat base salary to $565k; CFO Prabhu $330k; VP Bhat $340k, effective retroactive Jan 1, 2025.","2024 cash bonuses: Dr. Bhat $157,500; Mr. Prabhu $79,950; Ms. Bhat $77,500.","2025 bonus targets: 50% of base (CEO), 41% (CFO), 32% (VP), subject to Compensation Committee criteria.","Option grants at $1.80 strike: CEO 519k shares, CFO 194.25k, VP 181.5k; ~42% vested immediately, rest monthly through Dec 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-004224","json":"https://secwatch.observer/filing/0001437749-25-004224.json","markdown":"https://secwatch.observer/filing/0001437749-25-004224.md","text":"https://secwatch.observer/filing/0001437749-25-004224.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1742927/000143774925004224/0001437749-25-004224-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1742927/000143774925004224/rvph20250214_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T17:01:03.705455+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}